Literature DB >> 23873482

Clinical hypotension with co-prescription of macrolide antibiotics and calcium-channel blockers in haemodialysis patients: a retrospective chart review.

Swapnil Hiremath1, Marcel Ruzicka, Shankar Prasad Nagaraju, Brendan B McCormick.   

Abstract

BACKGROUND: Macrolide antibiotics inhibit the cytochrome p450 enzyme system, which metabolizes calcium-channel blockers. This may result in a clinically significant interaction, causing hypotension in patients co-prescribed these two drugs. Since these drugs are frequently used in the haemodialysis population, we studied the effect of their co-prescription on actual blood pressure.
METHODS: A retrospective chart review of all haemodialysis patients was conducted to identify patients co-prescribed a macrolide and a dihydropyridine calcium-channel blocker. Blood pressure measurements before and during the macrolide co-prescription were abstracted and compared using a student's t test.
RESULTS: We identified 154 haemodialysis patients concurrently prescribed a macrolide antibiotic and a dihydropyridine calcium-channel blocker. There was no significant difference in episodes of intra-dialytic hypotension or actual blood pressure measurements in the period before macrolide co-prescription and the period during macrolide co-prescription.
CONCLUSION: In contrast to hospitalized patients receiving dihydropyridine calcium-channel blockers, concurrent administration of a macrolide antibiotic for infection did not result in hypotension in haemodialysis outpatients. Further research should be undertaken before a change in clinical practice against their co-prescription is considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873482     DOI: 10.1007/s40264-013-0088-9

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  14 in total

Review 1.  Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics.

Authors:  Amy Henneman; Krisy-Ann Thornby
Journal:  Am J Health Syst Pharm       Date:  2012-06-15       Impact factor: 2.637

2.  Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events.

Authors:  Morten Schmidt; Martin B Johansen; Douglas J Robertson; Michael Maeng; Anne Kaltoft; Lisette O Jensen; Hans-Henrik Tilsted; Hans E Bøtker; Henrik Toft Sørensen; John A Baron
Journal:  Eur J Clin Invest       Date:  2011-08-11       Impact factor: 4.686

3.  K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.

Authors: 
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

4.  Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States.

Authors:  Blanche M Chavers; Craig A Solid; David T Gilbertson; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2007-01-24       Impact factor: 10.121

5.  EBPG guideline on haemodynamic instability.

Authors:  Jeroen Kooman; Ali Basci; Francesco Pizzarelli; Bernard Canaud; Patrick Haage; Denis Fouque; Klaus Konner; Alejandro Martin-Malo; Luciano Pedrini; James Tattersall; Jan Tordoir; Marianne Vennegoor; Christoph Wanner; Piet ter Wee; Raymond Vanholder
Journal:  Nephrol Dial Transplant       Date:  2007-05       Impact factor: 5.992

Review 6.  Macrolide drug interactions: an update.

Authors:  M P Pai; D M Graci; G W Amsden
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

7.  Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.

Authors:  Todd F Griffith; Benjamin S Y Chua; Andrew S Allen; Preston S Klassen; Donal N Reddan; Lynda A Szczech
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

8.  Absolute blood volume in hemodialysis patients: why is it relevant, and how to measure it?.

Authors:  Stephan Thijssen; Franz Kappel; Peter Kotanko
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

9.  Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP).

Authors:  Natalie H McInnis; George Fodor; Margaret Moy Lum-Kwong; Frans H H Leenen
Journal:  Am J Hypertens       Date:  2008-09-04       Impact factor: 2.689

10.  Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion.

Authors:  C H Kleinbloesem; P van Brummelen; A J Woittiez; H Faber; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.